Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $1.7 million.

  • Capricor Therapeutics' Non Operating Income rose 27810.56% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 12382.0%. This contributed to the annual value of $2.1 million for FY2024, which is 1716.67% up from last year.
  • Per Capricor Therapeutics' latest filing, its Non Operating Income stood at $1.7 million for Q3 2025, which was up 27810.56% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' Non Operating Income peaked at $1.8 million during Q2 2025, and registered a low of $9165.0 during Q1 2021.
  • Moreover, its 5-year median value for Non Operating Income was $434797.0 (2023), whereas its average is $548606.2.
  • Per our database at Business Quant, Capricor Therapeutics' Non Operating Income skyrocketed by 958221.6% in 2021 and then plummeted by 7213.89% in 2022.
  • Over the past 5 years, Capricor Therapeutics' Non Operating Income (Quarter) stood at $189118.0 in 2021, then surged by 82.65% to $345433.0 in 2022, then soared by 50.3% to $519203.0 in 2023, then rose by 11.95% to $581238.0 in 2024, then surged by 194.78% to $1.7 million in 2025.
  • Its Non Operating Income stands at $1.7 million for Q3 2025, versus $1.8 million for Q2 2025 and $581238.0 for Q4 2024.